Thrivent Financial for Lutherans Buys New Shares in Exact Sciences Co. (NASDAQ:EXAS)

Thrivent Financial for Lutherans bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 120,555 shares of the medical research company's stock, valued at approximately $6,774,000. Thrivent Financial for Lutherans owned approximately 0.07% of Exact Sciences at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in shares of Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after acquiring an additional 7,873 shares in the last quarter. Bellevue Group AG boosted its holdings in Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock valued at $98,738,000 after purchasing an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Exact Sciences by 3.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company's stock valued at $74,785,000 after purchasing an additional 38,849 shares during the last quarter. Groupama Asset Managment acquired a new stake in Exact Sciences during the third quarter worth approximately $821,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Exact Sciences by 63.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,262 shares of the medical research company's stock worth $30,863,000 after buying an additional 213,557 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EXAS has been the topic of a number of recent analyst reports. Scotiabank increased their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Benchmark restated a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. BTIG Research increased their price objective on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Finally, Barclays decreased their price target on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $70.83.

Exact Sciences Price Performance

NASDAQ EXAS traded down $1.58 during trading hours on Tuesday, reaching $45.52. The company's stock had a trading volume of 495,621 shares, compared to its average volume of 2,615,304. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The stock has a market cap of $8.45 billion, a PE ratio of -8.16 and a beta of 1.25. The company's 50-day moving average is $50.32 and its two-hundred day moving average is $58.18. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. Analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.